Alpha Teknova, Inc. Common Stock (TKNO) — Analysis Summary
Alpha Teknova, Inc. Common Stock (TKNO) has a market cap of $467.09M with year-over-year revenue growth of +7.4%. Net margin stands at -42.6%. The stock trades at a P/E ratio of -27.9.
Key Takeaways
- Revenue changed +7.4% year-over-year
- Net margin of -42.6%
- P/E ratio of -27.9
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, TKNO posted revenue growth of +7.4% and trades at a P/E of -27.9.
Alpha Teknova, Inc. Common Stock (TKNO)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -18.1x — earnings do not cover interest payments
Operating margin at -36.2% — material operating losses
Net margin at -38.4% — significant losses
The latest filing shows negative free cash flow.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees
158
Headquarters
HOLLISTER, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.